Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative Surgery vs Chemotherapy in Metastatic Gastric Cancer
NCT05230771Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Apr 2022
- Primary completion
- Mar 2024
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Fujian Medical University. Primary endpoint: 2-year Overall Survival Rate. Planned start Apr 2022; status: not yet recruiting.
Beyond the preview
Go deeper on NCT05230771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230771.